This website uses cookies, which are necessary for the technical operation of the website and are always set. Other cookies, which increase the comfort when using this website, are used for direct advertising or to facilitate interaction with other websites and social networks, are only set with your consent.
Configuration
Technically required
These cookies are necessary for the basic functions of the shop.
"Allow all cookies" cookie
"Decline all cookies" cookie
CSRF token
Cookie preferences
Currency change
Customer-specific caching
FACT-Finder tracking
Individual prices
Selected shop
Session
Comfort functions
These cookies are used to make the shopping experience even more appealing, for example for the recognition of the visitor.
Note
Show the facebook fanpage in the right blod sidebar
Statistics & Tracking
Affiliate program
Conversion and usertracking via Google Tag Manager
Soluble in DMSO. This research compound is the DMSO solvate form of trametinib. Trametinib is a selective MEK inhibitor. Trametinib inhibited MEK1/2 kinase activity, prevented Raf-dependent MEK phosphorylation, and produced prolonged p-ERK1/2 inhibition. It blocked the cell growth potently in most tumor lines with mutant BRAF or Ras. In xenograft tumor models, trametinib inhibited tumor growth, possibly by sustained suppression of p-ERK1/2, inhibition of tumor Ki67, and stimulation of p27Kip1/CDKN1B. The largest antitumor effect in vivo was among tumors harboring mutant BRAF or Ras. Gilmartin, A.G., et al. 'GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition.' Clin. Cancer Res. 17: 989-1000 (2011). A phase 1 clinical trial demonstrated substantial clinical activity of trametinib in human melanoma. Falchook, G.S., et al. 'Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.' Lancet Oncol. 13: 782-789 (2012). Trametinib improved rates of progression-free and overall survival among patients who had metastatic melanoma with a BRAF V600E or V600K mutation when compared with dacarbazine or paclitaxel. Flaherty, K.T., et al. 'Improved survival with MEK inhibition in BRAF-mutated melanoma.' N. Engl. J. Med. 367: 107-114 (2012). Both trametinib and leflunomide can suppress adjuvant-induced arthritis (AIA) and type II collagen-induced arthritis (CIA) development completely. In the CIA model, trametinib, but not leflunomide, inhibited collagen-reactive T-cell proliferation ex vivo, whereas leflunomide, but not trametinib, inhibited anti-collagen antibody production. Yamaguchi, T., et al. 'Suppressive effect of an orally active MEK1/2 inhibitor in two different animal models for rheumatoid arthritis: a comparison with leflunomide.' Inflamm. Res. 61: 445-454 (2012). For solid tumors, RAF/RAS mutation and the expression of the DUSP6 gene were strong predictors of sensitivity to trametinib. Among hematologic cell lines, acute and chronic myeloid leukemia cell lines were particularly sensitive to trametinib. Jing, J., et al. 'Comprehensive predictive biomarker analysis for MEK inhibitor GSK1120212.' Mol. Cancer Ther. 11: 720-729 (2012). Trametinib had favorable antitumor activities against colorectal cancers in vitro and in vivo. It exhibited an additive or a synergistic effect in combination with other chemotherapy agents including 5-fluorouracil, oxaliplatin, or SN-38. Yamaguchi, T., et al. 'Antitumor activities of JTP-74057 (GSK1120212), a novel MEK1/2 inhibitor, on colorectal cancer cell lines in vitro and in vivo.' Int. J. Oncol. 39: 23-31 (2011).
This website uses cookies, which are necessary for the technical operation of the website and are always set. Other cookies, which increase the usability of this website, serve for direct advertising or simplify interaction with other websites and social networks, will only be used with your consent.
More information